119 related articles for article (PubMed ID: 22650007)
1. Pharmacophoric studies of in vitro inhibition of Plasmodium falciparum growth.
Hariharan S
Indian J Biochem Biophys; 2012 Apr; 49(2):101-8. PubMed ID: 22650007
[TBL] [Abstract][Full Text] [Related]
2. Quantitative structure-activity relationships for gammadelta T cell activation by bisphosphonates.
Sanders JM; Ghosh S; Chan JM; Meints G; Wang H; Raker AM; Song Y; Colantino A; Burzynska A; Kafarski P; Morita CT; Oldfield E
J Med Chem; 2004 Jan; 47(2):375-84. PubMed ID: 14711309
[TBL] [Abstract][Full Text] [Related]
3. Structure-activity relationship study of antimalarial indolo [2,1-b]quinazoline-6,12-diones (tryptanthrins). Three dimensional pharmacophore modeling and identification of new antimalarial candidates.
Bhattacharjee AK; Hartell MG; Nichols DA; Hicks RP; Stanton B; van Hamont JE; Milhous WK
Eur J Med Chem; 2004 Jan; 39(1):59-67. PubMed ID: 14987834
[TBL] [Abstract][Full Text] [Related]
4. Nonbisphosphonate inhibitors of Plasmodium falciparum FPPS/GGPPS.
Kabeche S; Aida J; Akther T; Ichikawa T; Ochida A; Pulkoski-Gross MJ; Smith M; Humphries PS; Yeh E
Bioorg Med Chem Lett; 2021 Jun; 41():127978. PubMed ID: 33766764
[TBL] [Abstract][Full Text] [Related]
5. Understanding the structural requirements in diverse scaffolds for the inhibition of P. falciparum dihydroorotate dehydrogenase (PfDHODH) using 2D-QSAR, 3D-pharmacophore and structure-based energy- optimized pharmacophore models.
Aher RB; Roy K
Comb Chem High Throughput Screen; 2015; 18(2):217-26. PubMed ID: 25543684
[TBL] [Abstract][Full Text] [Related]
6. Pharmacophore modeling of substituted 1,2,4-Trioxanes for quantitative prediction of their antimalarial activity.
Gupta AK; Chakroborty S; Srivastava K; Puri SK; Saxena AK
J Chem Inf Model; 2010 Aug; 50(8):1510-20. PubMed ID: 20726605
[TBL] [Abstract][Full Text] [Related]
7. 3D QSAR, pharmacophore and molecular docking studies of known inhibitors and designing of novel inhibitors for M18 aspartyl aminopeptidase of Plasmodium falciparum.
Kumari M; Chandra S; Tiwari N; Subbarao N
BMC Struct Biol; 2016 Aug; 16():12. PubMed ID: 27534744
[TBL] [Abstract][Full Text] [Related]
8. A three-dimensional in silico pharmacophore model for inhibition of Plasmodium falciparum cyclin-dependent kinases and discovery of different classes of novel Pfmrk specific inhibitors.
Bhattacharjee AK; Geyer JA; Woodard CL; Kathcart AK; Nichols DA; Prigge ST; Li Z; Mott BT; Waters NC
J Med Chem; 2004 Oct; 47(22):5418-26. PubMed ID: 15481979
[TBL] [Abstract][Full Text] [Related]
9. Effects of bisphosphonates on the growth of Entamoeba histolytica and Plasmodium species in vitro and in vivo.
Ghosh S; Chan JM; Lea CR; Meints GA; Lewis JC; Tovian ZS; Flessner RM; Loftus TC; Bruchhaus I; Kendrick H; Croft SL; Kemp RG; Kobayashi S; Nozaki T; Oldfield E
J Med Chem; 2004 Jan; 47(1):175-87. PubMed ID: 14695831
[TBL] [Abstract][Full Text] [Related]
10. Ligand-based virtual screening and in silico design of new antimalarial compounds using nonstochastic and stochastic total and atom-type quadratic maps.
Marrero-Ponce Y; Iyarreta-VeitÃa M; Montero-Torres A; Romero-Zaldivar C; Brandt CA; Avila PE; Kirchgatter K; Machado Y
J Chem Inf Model; 2005; 45(4):1082-100. PubMed ID: 16045304
[TBL] [Abstract][Full Text] [Related]
11. Inhibitors of Plasmodium falciparum methionine aminopeptidase 1b possess antimalarial activity.
Chen X; Chong CR; Shi L; Yoshimoto T; Sullivan DJ; Liu JO
Proc Natl Acad Sci U S A; 2006 Sep; 103(39):14548-53. PubMed ID: 16983082
[TBL] [Abstract][Full Text] [Related]
12. Three-dimensional quantitative structure-activity relationship analysis of a set of Plasmodium falciparum dihydrofolate reductase inhibitors using a pharmacophore generation approach.
Parenti MD; Pacchioni S; Ferrari AM; Rastelli G
J Med Chem; 2004 Aug; 47(17):4258-67. PubMed ID: 15293997
[TBL] [Abstract][Full Text] [Related]
13. SAR and pharmacophore models for the rhodanine inhibitors of Plasmodium falciparum enoyl-acyl carrier protein reductase.
Kumar G; Banerjee T; Kapoor N; Surolia N; Surolia A
IUBMB Life; 2010 Mar; 62(3):204-13. PubMed ID: 20131353
[TBL] [Abstract][Full Text] [Related]
14. Insight into selectivity of peptidomimetic inhibitors with modified statine core for plasmepsin II of Plasmodium falciparum over human cathepsin D.
Dali B; Keita M; Megnassan E; Frecer V; Miertus S
Chem Biol Drug Des; 2012 Apr; 79(4):411-30. PubMed ID: 22129033
[TBL] [Abstract][Full Text] [Related]
15. Design and in silico screening of combinatorial library of antimalarial analogs of triclosan inhibiting Plasmodium falciparum enoyl-acyl carrier protein reductase.
Frecer V; Megnassan E; Miertus S
Eur J Med Chem; 2009 Jul; 44(7):3009-19. PubMed ID: 19217192
[TBL] [Abstract][Full Text] [Related]
16. A common feature-based 3D-pharmacophore model generation and virtual screening: identification of potential PfDHFR inhibitors.
Adane L; Bharatam PV; Sharma V
J Enzyme Inhib Med Chem; 2010 Oct; 25(5):635-45. PubMed ID: 19995305
[TBL] [Abstract][Full Text] [Related]
17. Characteristics of the Plasmodium falciparum PK5 ATP-binding site: implications for the design of novel antimalarial agents.
Keenan SM; Welsh WJ
J Mol Graph Model; 2004 Jan; 22(3):241-7. PubMed ID: 14629982
[TBL] [Abstract][Full Text] [Related]
18. Docking studies and development of novel 5-heteroarylamino-2,4-diamino-8-chloropyrimido-[4,5-b]quinolines as potential antimalarials.
Joshi AA; Viswanathan CL
Bioorg Med Chem Lett; 2006 May; 16(10):2613-7. PubMed ID: 16516468
[TBL] [Abstract][Full Text] [Related]
19. 3D-QSAR studies on triclosan derivatives as Plasmodium falciparum enoyl acyl carrier reductase inhibitors.
Shah P; Siddiqi MI
SAR QSAR Environ Res; 2010 Jul; 21(5-6):527-45. PubMed ID: 20818586
[TBL] [Abstract][Full Text] [Related]
20. 3D QSAR investigations on antimalarial naphthylisoquinoline alkaloids by comparative molecular similarity indices analysis (CoMSIA), based on different alignment approaches.
Bringmann G; Rummey C
J Chem Inf Comput Sci; 2003; 43(1):304-16. PubMed ID: 12546566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
